ELIQUENT Life Sciences Announces Acquisition Of Europe-Specific Regulatory Consultancy RApport Global Strategic Services

ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm serving the life sciences industry, announces the acquisition of RApport Global Strategic Services (RApport) . RApport is a UK-based international regulatory consultancy that supports life sciences innovators in obtaining and maintaining approvals for their products around the world. The acquisition of RApport is an important step for ELIQUENT towards international growth and expansion of its capabilities in Europe.

With RApport's European expertise, ELIQUENT expands its geographic reach and offers a dynamic portfolio of global regulatory consultancy services. The combined capabilities and services of both companies will provide end-to-end regulatory solutions to streamline development, go-to-market and compliance strategies across global markets.

"This announcement strengthens our position as a leader in the global regulatory consulting industry and demonstrates our commitment to delivering value to our customers," said Tim Dietlin, Chief Executive Officer of ELIQUENT Life Sciences. "We look forward to working with the talented RApport team to offer our customers a broad portfolio of solutions aimed at streamlining their global go-to-market and compliance strategies."

Iftikhar Saiyed, Co-Chief Executive Officer of RApport, said: "By joining forces, RApport and ELIQUENT will combine RApport's European expertise with ELIQUENT's extensive capabilities and services in the US and Asia Pacific. "This will create powerful synergies in the global regulatory arena." Additionally, the company's Co-Chief Executive Officer Lorna Griffin said, "This partnership allows RApport to expand its ability to provide comprehensive regulatory solutions to the life sciences industry."

RApport was advised by BDO LLP and Simons Muirhead Burton LLP and received supplemental strategic counseling from Indus Valley Advisors. ELIQUENT and GHO Capital were advised by Slaughter and May and Deloitte LLP.

About RApport

RApport Global Strategic Services is an international regulatory consulting firm providing regulatory support to the pharmaceutical, biotechnology and medical device industries. The RApport team is comprised of experienced regulatory professionals who are familiar with the global regulatory process. RApport provides global solutions including strategic and technical guidance, regulatory submissions, and post-market support for your entire development program.

About ELIQUENT

ELIQUENT Life Sciences is a fusion of five regulatory consultancies: Validant , Greenleaf Health , DataRevive , Oriel Stat-a-Matrix and IDEC . This unprecedented partnership brings together regulatory leaders, industry experts, and technology experts to provide comprehensive services to help pharmaceutical, biotech, and medical device companies navigate complex regulatory processes. We will promote

Supporting ELIQUENT's rapid growth strategy is GHO Capital, a European investment firm specializing in healthcare. Following our partnership with ELIQUENT Life Sciences (formerly Validant) in December 2018, this announcement marks the 2019 acquisition of DataRevive, a leading regulatory consulting firm in Japan, providing regulatory strategy and consulting for global clients. The November 2020 acquisition of IDEC, the December 2020 acquisition of Oriel STAT A MATRIX, a global consulting and training company for the medical device industry, and the April 2021 acquisition of Greenleaf Health, a leading FDA regulatory consulting firm. This is what continues.

About GHO

Global Healthcare Opportunities (or GHO Capital Partners LLP) is a leading healthcare-focused investment advisory firm based in London. With our global capabilities and perspective, we aim to exploit business opportunities in the rapidly evolving healthcare sector, and by internationalizing across Europe and the Atlantic, we aim to build a market-leading business with strategic global value. GHO Capital's investment track record is a testament to our unparalleled deep industry expertise and extensive network. We work with strong management teams to create long-term, sustainable value and deliver healthcare outcomes more efficiently, making healthcare better, faster and more accessible. For more information, please visit www.ghocapital.com .

The official version of this press release is the original language version. Translated language versions are provided for the convenience of the reader and have no legal effect. When using a translated language version as a document, please compare it with the original language version, which is the only legally enforceable version.

Contacts

Taryn Fritz Walpole
twalpole@eliquent.com
202-445-7679